Join
Live feed
·
PRReleasevia Quantisnow
Crescent Biopharma Inc. logo

Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001

ByQuantisnow·Wall Street's wire, on your screen.
CBIO· Crescent Biopharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CBIO (Crescent Biopharma Inc.) and more on Quantisnow.